Avidity Biosciences (RNA) Expected to Announce Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Avidity Biosciences to announce earnings of ($1.4175) per share and revenue of $0.6670 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 20, 2026 at 4:00 PM ET.

Avidity Biosciences (NASDAQ:RNA) last released its earnings results on Thursday, May 14th. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.08. The company had revenue of $19.64 million during the quarter, compared to analysts’ expectations of $2.00 million. On average, analysts expect Avidity Biosciences to post $-6 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Avidity Biosciences Stock Up 0.2%

NASDAQ:RNA opened at $12.27 on Wednesday. The company has a market cap of $209.94 million and a P/E ratio of -12.65. Avidity Biosciences has a fifty-two week low of $11.13 and a fifty-two week high of $16.77. The firm’s 50 day moving average is $12.35 and its two-hundred day moving average is $23.98.

Institutional Investors Weigh In On Avidity Biosciences

Several institutional investors have recently bought and sold shares of RNA. Royal Bank of Canada raised its stake in shares of Avidity Biosciences by 38.2% in the 1st quarter. Royal Bank of Canada now owns 44,304 shares of the biotechnology company’s stock valued at $1,308,000 after acquiring an additional 12,241 shares during the period. NewEdge Advisors LLC boosted its position in Avidity Biosciences by 22.7% during the 1st quarter. NewEdge Advisors LLC now owns 23,837 shares of the biotechnology company’s stock worth $704,000 after purchasing an additional 4,410 shares during the period. Goldman Sachs Group Inc. boosted its position in Avidity Biosciences by 2.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 784,704 shares of the biotechnology company’s stock worth $23,164,000 after purchasing an additional 21,649 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Avidity Biosciences by 7.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 357,718 shares of the biotechnology company’s stock valued at $10,560,000 after purchasing an additional 25,329 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Avidity Biosciences in the 1st quarter valued at $180,000.

Analysts Set New Price Targets

Several analysts have recently issued reports on RNA shares. Cantor Fitzgerald started coverage on shares of Avidity Biosciences in a research note on Thursday, June 18th. They set an “overweight” rating and a $25.00 price objective for the company. Zacks Research raised Avidity Biosciences to a “hold” rating in a research report on Friday, June 19th. Weiss Ratings upgraded Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. HC Wainwright initiated coverage on Avidity Biosciences in a research report on Thursday, August 6th. They set a “buy” rating and a $25.00 price target for the company. Finally, Wall Street Zen raised Avidity Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 30th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Avidity Biosciences currently has a consensus rating of “Hold” and a consensus price target of $63.85.

About Avidity Biosciences

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.